Subcutaneous Methotrexate to Cut Costs?

Journal of Rheumatology

Volumn 39, Issue 8, 2012, Pages 1764-1765

  Hassanzadeh, Roya ^a   Mangan, Clodagh ^a   France, Janice ^b   Bawa, Sandeep ^b  

^a UNIVERSITY OF GLASGOW   (United Kingdom)

^b GARTNAVEL GENERAL HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

METHOTREXATE; TUMOR NECROSIS FACTOR INHIBITOR;

COST CONTROL; DRUG BIOAVAILABILITY; DRUG CHOICE; DRUG COST; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; HUMAN; LETTER; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS; UNSPECIFIED SIDE EFFECT;

ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; HEALTH CARE COSTS; HUMANS; INFUSIONS, SUBCUTANEOUS; METHOTREXATE; RETROSPECTIVE STUDIES;

EID: 84864571547     PISSN: 0315162X     EISSN: 14992752     Source Type: Journal    
DOI: 10.3899/jrheum.120091     Document Type: Letter

References (10)

1. British Society for Rheumatology. British Society for Rheumatology and British Health Professionals in Rheumatology guideline for the management of rheumatoid arthritis (after the first 2 years); 2010. [Internet. Accessed May 1, 2012.] Available from: http://www.rheumatology.org.uk/resources/guidelines/bsr- guidelines.aspx
2. British Society for Rheumatology Biologics Register (BSRBR). Changes in disease characteristics and response rates among patients in the United Kingdom starting anti-tumour necrosis factor therapy for rheumatoid arthritis between 2001 and 2008. Rheumatology 2011;50:117-23.
3. British Society for Rheumatology. Rates of serious infection, including site-specific and bacterial intracellular infection, in rheumatoid arthritis patients receiving anti-tumor necrosis factor therapy. Arthritis Rheum 2008;54:2368-76.
4. National Institute for Health and Clinical Excellence. Rheumatoid arthritis: The management of rheumatoid arthritis in adults; 2009. [Internet. Accessed May 1, 2012.] Available from: www.nice.org.uk
5. Braun J, Kaestner P, Flaxenberg P, Waehrisch J, Hanke P, Demary W. Comparison of the clinical efficacy and safety of subcutaneous versus oral administration of methotrexate in patients with active rheumatoid arthritis. Arthritis Rheum 2008;58:73-81.
6. Rutkowska-Sak L, Rell-Bakalarska M, Lisowska B. Oral vs. Subcutaneous low dose methotrexate treatment in reducing gastrointestinal side effects. Reumatologica 2009;47:207-11.
7. Hoekstra M, Haagsma C, Neef C, Proost J, Knuif A, van de Laar M. Bioavailability of higher dose methotrexate comparing oral and subcutaneous administration in patients with rheumatoid arthritis. J Rheumatol 2004;31:645-8. (Pubitemid 38451248)
8. Hamilton RA, Kremer JM. Why intramuscular methotrexate may be more efficacious than oral dosing in patients with rheumatoid arthritis. Br J Rheumatol 1997;36:86-90.
9. National Audit Office. Department of Health: Management of NHS hospital productivity. [Internet. Accessed May 1, 2012.] Available from: http://www.nao.org.uk/publications/1011/nhs-hospital-productivity.aspx
10. World Health Organization. Chronic diseases and health promotion: Chronic rheumatic conditions. [Internet. Accessed May 1, 2012.] Available from: http://www.who.int/chp/topics/rheumatic/en/